At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, delivered a talk on “Personalizing Treatment in the Frontline Setting”.
He emphasized that there is no “one-size-fits-all” approach in oncology. Personalization depends not only on patient factors, tumor biology, and the immune system, but also on geography and treatment accessibility. Precision medicine, he noted, extends beyond genetics and must consider the real-world availability of therapies.
According to Dr. Ürün, three pillars guide treatment decisions: the biology of the disease, the treatment context including geography, and the expectations and values of patients. In kidney cancer, tumors driven by VEGF-mediated angiogenesis illustrate how understanding tumor biology is central to therapeutic choices.
He highlighted the critical importance of selecting the best first-line therapy, as many patients may not be able to proceed to subsequent treatment lines. The first-line decision often shapes the entire course of care, making it essential to consider tumor biology, patient characteristics, treatment tolerability, and real-world access when choosing initial therapy.
Personalized treatment decisions require balancing scientific evidence with patient-specific factors and practical considerations, reflecting a holistic approach that extends beyond guidelines to ensure individualized care in real-world practice.
Join us in the conversation.